$230M deal: AstraZeneca forms COPD drugs collaboration

AstraZeneca entered a collaboration with Circassia Pharmaceuticals for the the development and commercialization of two inhaled respiratory medicines for the treatment of chronic obstructive pulmonary disease, or COPD. The deal, which has a total value of up to $230 million, covers Tudorza and Duaklir. Tudorza was approved and launched in the United States in 2012. Duaklir is expected to be submitted to the FOod and Drug Administration for regulatory review in 2018. Under the terms of the proposed…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news